Literature DB >> 2536345

Stability and reactivation of tyrosine radicals from ribonucleotide reductase in tumor cells studied by ESR.

G Lassmann1, B Liermann, P Langen.   

Abstract

Naturally occurring tyrosine radicals from the M2 subunit of ribonucleotide reductase (RR) have been recorded by ESR in proliferating ordinary Ehrlich-ascites (EA) tumor cells of mice. Tyrosine radicals are stable in EA cells at room temperature for 2 h. Up to 500 mW no microwave saturation occurs. The relatively high stability and non-saturation of tyrosine radicals in EA cells suggests a suitable protein conformation in the M2 subunit enabling a close contact between the tyrosine radical and the antiferromagnetic iron complex. This facilitates an ESR study of functionally essential tyrosine radicals of RR in EA cells at low temperature and recommends this cellular system for studying such processes as inhibition and activation, which change the content of tyrosine radicals of the proliferation-linked RR. Oxygen treatment of non-proliferating (quiescent) EA cells reactivates tyrosine radicals 2-3 fold as found in strongly proliferating cells. We conclude that in quiescent cells, suffering from a lack of oxygen due to their high density in the peritoneal cavity, a reactivation of tyrosine radicals occurs by oxidation of non-radical tyrosine residues of inactive M2 subunits.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536345     DOI: 10.1016/0891-5849(89)90153-6

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  2 in total

1.  Direct ESR detection or peroxynitrite-induced tyrosine-centred protein radicals in human blood plasma.

Authors:  D Pietraforte; M Minetti
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.

Authors:  G Lassmanm; B Liermann; W Arnold; K Schwabe
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.